BeOne Medicines Ltd. (HKG:6160)

Market Cap	263.71B
Revenue (ttm)	32.53B
Net Income (ttm)	-3.07B
Shares Out	n/a
EPS (ttm)	-29.20
PE Ratio	n/a
Forward PE	110.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,171,119
Average Volume	6,231,207
Open	161.70
Previous Close	162.40
Day's Range	157.70 - 163.70
52-Week Range	85.00 - 178.00
Beta	0.30
RSI	62.92
Earnings Date	May 14, 2025

About BeOne Medicines

BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6160

Financial Performance

In 2024, BeOne Medicines's revenue was 27.81 billion, an increase of 59.51% compared to the previous year's 17.43 billion. Losses were -4.71 billion, -24.72% less than in 2023.

Financial numbers in CNY